Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
SynAct Pharma AB is a clinical-stage biotechnology company based in Lund, Sweden, specializing in the development of innovative medicines that induce resolution of inflammation rather than merely inhibiting it. Its lead candidate, resomelagon (AP1189), is a first-in-class, once-daily oral tablet that selectively activates melanocortin type 1 and 3 receptors on immune cells, promoting immune balance and clearance of inflammatory cells without immunosuppression. This approach targets acute impairments in inflammatory diseases, including newly diagnosed rheumatoid arthritis with high disease activity and psoriasis arthritis, as well as hyperinflammatory stages in severe viral infections like Dengue fever, where Phase 2 studies are ongoing. SynAct Pharma AB also advances a pipeline featuring preclinical peptide melanocortin agonists, such as TXP-11 for intravenous use in preserving organ function in high-risk hospitalized patients. With a small team of six employees and a science-driven strategy, the company addresses unmet needs in autoimmune and inflammatory conditions, aiming to reduce disease progression, limit reliance on less tolerable treatments, and enable faster recovery across a broad spectrum of unmet medical needs in biotechnology and medical research.
kr 1.36
kr 0.02 (-1.30%)
EOD Jun 26, 2026 · Twelve Data
ROIC dropped from -36.19% to -47.41%, capital efficiency is deteriorating. Negative free cash flow of -kr 97M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 112M
▼ -34.5% YoY
Op. Margin
—
ROIC
-47.41%
▼ -11.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 101M
▼ -9.1% YoY
Op. Cash Flow (TTM)
-kr 100M
▼ -9.1% YoY
Net Debt
-kr 52M
Net Cash Position
Cash & Equiv.
kr 53M
Continue Research
SynAct Pharma AB (SYNACT.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, SynAct Pharma AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
SynAct Pharma AB scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -47.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SYNACT.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.